Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Hastings Insider Profile
4 Followers
Paul Hastings, Chairman & CEO, Director at OncoMed Pharma, holds 319.86K shares in Nkarta (Ticker: NKTX), holds 12.72K shares in Pacira Pharmaceuticals (Ticker: PCRX), holds 346.87K shares in OncoMed Pharma (Ticker: OMED). Most recently, Paul Hastings Sold ― shares of Nkarta on Jan 17, 2025 for an estimated value of 38.23K.
Paul Hastings OncoMed Pharma (OMED)Chairman & CEO, Director
OncoMed Pharma (OMED)
Chairman & CEO, Director
Ranked #11,657 out of 100,516 Corporate Insiders
Profitable Transactions
5 out of 9 Profitable Transactions
Average Return
+17.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Paul Hastings holds in companies
Most Profitable Insider Trade
The most profitable trade made by Paul Hastings
Paul Hastings's Trading History
OncoMed Pharma
Oct 12, 2017
―
Informative Sell
5.93K
$308.71K
Protara Therapeutics
Oct 20, 2016
Director
Uninformative Buy
―
―
Nkarta
Jan 17, 2025
CEO, Director
Informative Sell
38.23K
$706.89K
enGene Holdings
―
Director
―
―
Pacira Pharmaceuticals
Jun 13, 2024
Director
Uninformative Buy
―
$323.70K
Relypsa Inc
Jun 23, 2016
―
Uninformative Buy
―
$112.22K
Novelion Therapeutics
―
―
―
$6.67K
List of latest transactions for each holding click on a transaction to see Paul Hastings's performance on stock
You May Also Like
Paul Hastings insider profile FAQ
What is the percentage of profitable transactions made by Paul Hastings?
The percentage of profitable transactions made by Paul Hastings is 56%.
What is the average return per transaction made by Paul Hastings?
The average return per transaction made by Paul Hastings is 17.40%.
What stocks does Paul Hastings hold?
Paul Hastings holds: OMED, TARA, NKTX, ENGN, PCRX, RLYP, NVLNF stocks.
What was Paul Hastings’s latest transaction?
Paul Hastings latest transaction was an Informative Sell of $38.23K.
What was Paul Hastings's most profitable transaction?
Paul Hastings’s most profitable transaction was an Informative Sell of NKTX stock on January 18, 2024. The return on the trade was 70.90%.
What is Paul Hastings's role in OncoMed Pharma?
Paul Hastings's role in OncoMed Pharma is Chairman & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.